Plain-English translation of NCT05033080 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Cystic fibrosis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested VX-121/tezacaftor/deutivacaftor, a new three-drug combination, to see how well it worked compared to an existing treatment called elexacaftor/tezacaftor/ivacaftor. The study included people with cystic fibrosis who carry two specific genetic mutations (F508del and a minimal function mutation). Researchers were looking to see whether the new medication could help participants breathe better and manage their disease.
People with cystic fibrosis who carry these two particular mutations have limited treatment options. This study was designed to test whether this medication could offer a new, potentially better option for managing their lung disease.
Participants started with a 4-week run-in period where everyone took the standard three-drug treatment to establish a baseline. They were then randomly assigned to either continue the standard treatment or switch to the new medication combination for 52 weeks. Throughout the year, participants would have had regular visits to take their medication, complete breathing tests, and have their health monitored to see how well the treatment worked.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
United States